MedPath

Exploring the utility of circulating tumor DNA in neoadjuvant setting

Not Applicable
Completed
Conditions
Health Condition 1: null- Breast Cancer
Registration Number
CTRI/2016/09/007308
Lead Sponsor
DEPARTMENT OF BIOTECHNOLOGY
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
15
Inclusion Criteria

•Patients just diagnosed with breast cancer and planned for NACT.

•Patients willing to provide written informed consent to participate in the study.

•Patients whose tumors have any receptor phenotype.

•Patients willing to receive the usual standard treatment in NACT setting

Exclusion Criteria

Patients with metastatic disease will not be included.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath